Sumitomo Mitsui Trust Holdings Inc. Decreases Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Sumitomo Mitsui Trust Holdings Inc. lessened its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 0.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 162,434 shares of the specialty pharmaceutical company’s stock after selling 1,177 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned 0.26% of Jazz Pharmaceuticals worth $19,979,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in JAZZ. Vontobel Holding Ltd. raised its position in Jazz Pharmaceuticals by 6.2% in the 3rd quarter. Vontobel Holding Ltd. now owns 4,847 shares of the specialty pharmaceutical company’s stock worth $627,000 after purchasing an additional 281 shares during the period. SG Americas Securities LLC purchased a new position in Jazz Pharmaceuticals in the 3rd quarter worth $611,000. Exchange Traded Concepts LLC grew its holdings in Jazz Pharmaceuticals by 6.6% in the 3rd quarter. Exchange Traded Concepts LLC now owns 4,604 shares of the specialty pharmaceutical company’s stock worth $596,000 after acquiring an additional 284 shares during the last quarter. Asset Management One Co. Ltd. grew its holdings in Jazz Pharmaceuticals by 12.0% in the 3rd quarter. Asset Management One Co. Ltd. now owns 28,124 shares of the specialty pharmaceutical company’s stock worth $3,640,000 after acquiring an additional 3,004 shares during the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in Jazz Pharmaceuticals by 10.6% in the 3rd quarter. Commonwealth Equity Services LLC now owns 10,073 shares of the specialty pharmaceutical company’s stock worth $1,304,000 after acquiring an additional 962 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Insider Activity

In other Jazz Pharmaceuticals news, CFO Philip L. Johnson purchased 12,000 shares of the stock in a transaction dated Friday, March 1st. The shares were purchased at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CFO Philip L. Johnson bought 12,000 shares of the stock in a transaction on Friday, March 1st. The shares were bought at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Patricia Carr sold 1,936 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares in the company, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company’s stock.

Jazz Pharmaceuticals Trading Down 1.0 %

Jazz Pharmaceuticals stock opened at $108.83 on Tuesday. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37. The business’s fifty day simple moving average is $119.51 and its two-hundred day simple moving average is $122.28. Jazz Pharmaceuticals plc has a 12 month low of $106.61 and a 12 month high of $146.70. The company has a market capitalization of $6.86 billion, a price-to-earnings ratio of 17.78, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. As a group, equities analysts predict that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of recent analyst reports. Stifel Nicolaus raised their price target on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a report on Friday, March 15th. Cantor Fitzgerald reissued an “overweight” rating and issued a $180.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Truist Financial reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Robert W. Baird initiated coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $160.00 price target on the stock. Finally, JPMorgan Chase & Co. raised their price target on shares of Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $195.08.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.